mufa 22:1 n-9

MUFA 22:1 n‑9, chemically known as cis‑13‑docosenoic acid and commonly referred to as erucic acid, is a long‑chain monounsaturated fatty acid with 22 carbon atoms and one double bond in the omega‑9 position. This fatty acid belongs to the MUFA family, which includes other single‑double‑bond lipids like oleic acid, though erucic acid itself occurs in relatively limited dietary sources compared with more common MUFAs. Monounsaturated fatty acids are defined by a single cis double bond affecting the lipid’s physical properties and biological roles, such as influencing membrane fluidity and participating in cellular metabolism. While essential fatty acids such as omega‑3 and omega‑6 types must be obtained from diet, erucic acid can be synthesized endogenously from other unsaturated fats, and therefore it is not classified as an essential nutrient requiring a recommended dietary allowance (RDA). In fact, erucic acid historically has been viewed with caution due to experimental evidence from animal models indicating potential cardiotoxicity at high doses. These findings led food safety authorities in the United States and Europe to regulate its concentration in edible oils, particularly rapeseed and mustard oil, to low levels suitable for human consumption. Modern cultivated rapeseed varieties (e.g., Canola) contain only minimal erucic acid due to selective breeding, minimizing potential risk. The fatty acid’s presence in foods is often incidental, and it can also appear at trace levels in processed foods, animal fats, and seafood, reflecting the complex lipid profiles in various edible sources. Researchers continue to explore the biochemical activities of erucic acid due to its unique structure and potential pharmacological roles, though robust human health benefit data are limited, and the compound is generally not promoted as a nutrient supplement.

Erucic acid (MUFA 22:1 n‑9) falls within the broader class of monounsaturated fatty acids (MUFAs), a category of dietary lipids recognized for roles in human metabolism and cardiovascular health when consumed as part of typical dietary fats. Unlike essential omega‑3 and omega‑6 fatty acids, erucic acid itself is not required for normal physiological functions. Rather, its relevance arises from its occurrence within complex dietary fats and as a metabolic intermediate. Monounsaturated fatty acids, including erucic acid, contribute to the total fat content in foods and can influence lipid metabolism, cell membrane composition, and energy storage dynamics. Studies on MUFAs generally have associated higher intake of monounsaturated fats, particularly oleic acid, with favorable effects on low‑density lipoprotein (LDL) cholesterol and high‑density lipoprotein (HDL) cholesterol levels, potentially reducing cardiovascular disease risk when replacing saturated fats in the diet. However, these benefits have been demonstrated for MUFAs as a class, not specifically for erucic acid. Erucic acid’s distinct long‑chain structure prompted animal studies in the mid‑20th century that reported myocardial lipidosis at very high intake levels, indicating accumulation of lipids in cardiac tissue. These findings raised safety concerns rather than demonstrating health benefits and led to regulatory limits on its concentration in food oils. Recent scientific reviews suggest that while historic animal data point to potential toxicological effects at excessive doses, human data are scarce, and more research is needed to clarify any biological roles beyond being part of dietary fat mixtures. Some pharmacological investigations explore whether erucic acid might exert cytotoxic or neuroprotective effects in laboratory settings, but such findings remain preliminary and not robustly evidenced in clinical human studies. Thus, erucic acid’s principal recognized health impact relates to dietary fat quality and exposure safety rather than specific beneficial functions distinct from other MUFAs.

Because erucic acid (MUFA 22:1 n‑9) is not classified as an essential nutrient, authoritative bodies such as the National Institutes of Health Office of Dietary Supplements have not established Recommended Dietary Allowances or Adequate Intakes for this fatty acid. Unlike essential vitamins, minerals, or fatty acids such as alpha‑linolenic acid, erucic acid can be synthesized endogenously from other dietary unsaturated fats, and the body does not require a specific intake for normal function. Modern dietary guidance focuses on limiting erucic acid exposure rather than recommending a target intake. Food regulatory agencies have developed tolerable daily intake (TDI) estimates based on toxicological data. For example, the European Food Safety Authority has proposed a TDI for erucic acid of approximately 7 mg per kilogram of body weight per day, derived from animal studies assessing cardiac lipid accumulation and other risk endpoints. This TDI serves as a safety reference rather than a nutritional requirement and is intended to minimize the potential for adverse effects, especially in sensitive populations such as infants and young children who may be exposed through complementary feeding or formula containing vegetable oils. Dietary patterns in populations consuming foods low in erucic acid (e.g., Canola oil with ≤2% erucic acid of total fatty acids) typically result in intakes well below these risk‑based thresholds, and average consumption of erucic acid in the Western diet is low given regulatory controls and modern breeding of crop varieties. Because no physiological requirement exists, intakes are generally considered from a risk management perspective, and individuals are advised to focus on overall dietary fat quality and balance among essential fatty acid intakes rather than targeting erucic acid.

As erucic acid (MUFA 22:1 n‑9) is not essential for human nutrition, there is no clinical deficiency syndrome attributable to an inadequate intake of this specific fatty acid. Unlike essential fatty acids such as linoleic acid or alpha‑linolenic acid, which are required for normal cellular function and must be obtained through diet, erucic acid can be synthesized endogenously from other monounsaturated fats, and the body does not depend on dietary erucic acid to maintain physiological integrity. Consequently, typical deficiency symptoms, diagnostic criteria, or prevalence statistics specific to erucic acid absence do not exist in the scientific literature. Instead, clinical concern historically has centered around excessive exposure at high levels, primarily from diets containing large quantities of high‑erucic acid oils, rather than insufficient intake. Animal studies showed that very high doses of erucic acid led to myocardial lipidosis and hepatic lipid accumulation, but these are not deficiency states; they are toxic exposures observed under experimental conditions at levels far above typical dietary intakes. Regulatory authorities have responded by limiting erucic acid content in food oils such as rapeseed and mustard oil, and modern food supplies in many regions contain only trace amounts due to low‑erucic acid cultivars. Therefore, healthcare providers and nutrition scientists do not assess erucic acid deficiency, and clinical evaluations for lipid‑related disorders focus on overall fatty acid balance, essential fatty acid status, and total dietary fat quality rather than levels of this specific MUFA.

Erucic acid (MUFA 22:1 n‑9) is found in a variety of foods in small to moderate amounts, though its presence in the modern food supply has decreased due to regulatory limits on high‑erucic acid oils. Traditional sources include certain seed oils from plants of the Brassicaceae family, such as mustard and historical rapeseed varieties, which once contained high proportions of erucic acid. Today, most edible rapeseed oil (e.g., Canola oil) is bred for low erucic acid content (typically ≤2% of total fatty acids), minimizing exposure while retaining beneficial monounsaturated fats like oleic acid. In addition to vegetable oils, erucic acid may occur in animal fats and processed foods containing animal fats. Seafood and fish oils, particularly those rich in total fat content, can also contribute detectable amounts. A survey of foods shows a wide array of items containing measurable erucic acid, including plant oils, processed meats, dairy products, nuts, seeds, and seafood, though quantities vary widely and are generally low due to food production standards. For example, peanut oil and safflower oil can contain modest amounts of erucic acid per 100 g, while processed meats such as beef frankfurters and breakfast sausages also contribute small amounts. Baked goods and dairy products contain trace levels, reflecting the complexity of mixed dietary fats. Notably, seafood products such as salmon and mackerel may contain erucic acid depending on species and feed composition, with some wild and farmed fish showing higher total lipid content correlating with increased levels of very long‑chain monounsaturated fatty acids. While erucic acid is present across many food categories, it is not considered a targeted nutrient for dietary planning. Instead, individuals seeking healthy fat patterns should emphasize sources rich in beneficial MUFAs and essential fatty acids, such as olive oil, avocados, nuts, seeds, and fatty fish, while acknowledging the incidental presence of erucic acid within broader dietary fats.

Erucic acid, like other dietary fatty acids, is absorbed in the small intestine following emulsification by bile salts and incorporation into micelles. Pancreatic lipases hydrolyze triglycerides containing erucic acid, releasing free fatty acids and monoacylglycerols that enter enterocytes. Within enterocytes, erucic acid is re‑esterified into triglycerides and packaged into chylomicrons for transport through the lymphatic system to the bloodstream. As a long‑chain fatty acid, erucic acid follows similar metabolic pathways to other MUFAs, with beta‑oxidation occurring in mitochondria for energy production or incorporation into cellular lipid pools. Bioavailability may vary based on the food matrix, fat content, and presence of other dietary factors such as fiber and polyphenols, which can modulate overall fat digestion and absorption. Because erucic acid typically occurs at low concentrations in the modern food supply, its specific absorption kinetics have not been extensively studied compared with more abundant fatty acids like oleic acid. However, general principles of lipid digestion apply, and factors known to enhance fat absorption—such as co‑consumption of dietary fat and adequate bile salt secretion—improve uptake of all long‑chain fatty acids.

Supplements specifically containing erucic acid are not commonly recommended, as this fatty acid is not essential and has no established nutritional requirement. Unlike omega‑3 supplements that supply essential fatty acids like EPA and DHA, erucic acid supplementation does not confer recognized health benefits and may pose risk if consumed at high doses. Historical toxicological data from animal models indicated that excessive intake could lead to lipid accumulation in cardiac tissue, prompting regulation and reduction of erucic acid content in food oils rather than promotion of supplemental intake. Some niche research explores pharmacological properties of erucic acid derivatives, but these investigations are not sufficient to support general supplement use. Therefore, most individuals do not require erucic acid supplements, and focus should remain on obtaining a balanced profile of dietary fats through foods rich in beneficial monounsaturated and essential polyunsaturated fatty acids instead.

Although erucic acid is not essential, its potential toxicity at high intake levels has driven regulatory oversight. Animal studies conducted in the mid‑20th century demonstrated that diets with high levels of erucic acid led to myocardial lipidosis, a reversible accumulation of triglycerides in heart muscle cells. Based on toxicological evidence, authorities such as the European Food Safety Authority proposed a tolerable daily intake of approximately 7 mg erucic acid per kg body weight per day to minimize risk, particularly in sensitive populations. Regulatory frameworks in the United States and Europe set maximum allowable concentrations of erucic acid in edible oils to keep routine dietary exposure well below levels associated with adverse effects in experimental models. Modern Canola oils and other food‑grade seed oils contain minimal erucic acid as a result of selective breeding to reduce this component. Toxicity concerns for humans have not been definitively confirmed at typical dietary exposures; however, caution in food production has ensured low presence in the food supply. Symptoms of excessive exposure in animal models included altered cardiac metabolism and lipid deposition, and similar effects in humans remain a theoretical concern at very high intake. Appropriate food selection and adherence to regulatory standards effectively minimizes risk of erucic acid toxicity in the general population.

There is no well‑documented evidence of specific drug interactions unique to erucic acid (MUFA 22:1 n‑9) in standard clinical references. As a fatty acid present at low levels in the diet, erucic acid is metabolized via typical lipid pathways that do not directly interfere with most medications. However, high intake of certain dietary fats can influence the pharmacokinetics of fat‑soluble drugs by altering gastrointestinal motility or bile secretion, potentially affecting absorption of medications with fat‑dependent bioavailability. Individuals taking medications that require administration with or without food should follow specific guidance on timing relative to meals rather than targeting erucic acid per se. Patients with cardiovascular conditions on lipid‑modifying therapies (e.g., statins) should focus on overall dietary fat quality rather than specific fatty acids like erucic acid. Always consult healthcare providers regarding medication and dietary fat interactions.